Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells

Guo,Jing; Chen,Li; Luo,Ning; Yang,Weihong; Qu,Xiaoyan; Cheng,Zhongping

doi:10.3892/or.2015.3902

Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells

Authors:
- Jing Guo
- Li Chen
- Ning Luo
- Weihong Yang
- Xiaoyan Qu
- Zhongping Cheng
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Yangpu Hospital, Tongji University School of Medicine, Shanghai, P.R. China
Published online on: April 7, 2015 https://doi.org/10.3892/or.2015.3902
Pages: 3124-3130

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The association of TMEM45A with various cancers has been recently reported. However, the biological function of TMEM45A in ovarian cancer remains unclear. The present study aimed to elucidate the role of TMEM45A in regulating the biological behavior of ovarian cancer cells. We compared the expression of TMEM45A between ovarian cancer tissues and normal tissues based on RNA-sequencing data of the ovarian cancer cohort from The Cancer Genome Atlas (TCGA) project and our real-time PCR data from 25 pairs of ovarian cancer and their matched non-cancerous tissue samples. The expression of TMEM45A was then suppressed in two ovarian cancer cell lines, HO-8910 and A2780, by RNA interference. Cell proliferation, cell cycle distribution, adhesion and invasive ability were then detected using the Cell Counting Kit-8 assay (CCK-8), propidium iodide (PI) staining, and cell adhesion and Transwell assays, respectively. In addition, the mRNA and protein levels of transforming growth factor-β (TGF-β1 and TGF-β2), Ras homolog family member A (RhoA) and Rho-associated kinase 2 (ROCK2) were detected with real-time PCR and western blotting, respectively. TCGA data and our real-time PCR results demonstrated the overexpression of TMEM45A in ovarian cancer. Silencing of TMEM45A significantly inhibited cell proliferation and significantly increased the cell population in the G1 phase. Moreover, knockdown of TMEM45A also inhibited cell adhesion as well as cell invasion. More importantly, suppression of TMEM45A notably downregulated the expression of TGF-β1, TGF-β2, RhoA and ROCK2. In conclusion, TMEM45A may function as an oncogene for ovarian cancer, and inhibition of TMEM45A may be a therapeutic strategy for ovarian cancer.

View Figures

View References

1	Zeinoun Z, Teugels E, De Bleser PJ, Neyns B, Geerts A and De Greve J: Insufficient TGF-beta 1 production inactivates the autocrine growth suppressive circuit in human ovarian cancer cell lines. Anticancer Res. 19:413–420. 1999.PubMed/NCBI
2	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
3	Cannistra SA: Cancer of the ovary. N Engl J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
4	Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA and Cannistra SA: Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 22:4700–4710. 2004. View Article : Google Scholar : PubMed/NCBI
5	Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, et al: Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 11:3686–3696. 2005. View Article : Google Scholar : PubMed/NCBI
6	Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, et al: Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 11:2149–2155. 2005. View Article : Google Scholar : PubMed/NCBI
7	Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA and Cannistra SA: Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol. 23:7911–7918. 2005. View Article : Google Scholar : PubMed/NCBI
8	Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, et al: Molecular profiling of platinum resistant ovarian cancer. Int J Cancer. 118:1963–1971. 2006. View Article : Google Scholar
9	Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, et al: An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 25:517–525. 2007. View Article : Google Scholar : PubMed/NCBI
10	Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de Vries EG, et al: Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 6:e242009. View Article : Google Scholar : PubMed/NCBI
11	Flamant L, Roegiers E, Pierre M, Hayez A, Sterpin C, De Backer O, Arnould T, Poumay Y and Michiels C: TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer. 12:3912012. View Article : Google Scholar : PubMed/NCBI
12	Urquidi V, Goodison S, Cai Y, Sun Y and Rosser CJ: A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev. 21:2149–2158. 2012. View Article : Google Scholar : PubMed/NCBI
13	Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, Pairojkul C and Nakamura Y: Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic chol-angiocarcinoma. Hepatology. 44:1025–1038. 2006. View Article : Google Scholar : PubMed/NCBI
14	Hsieh TC and Wu JM: Differential control of growth, cell cycle progression, and gene expression in human estrogen receptor positive MCF-7 breast cancer cells by extracts derived from polysaccharopeptide I’m-Yunity and Danshen and their combination. Int J Oncol. 29:1215–1222. 2006.PubMed/NCBI
15	Subramanian A, Kuehn H, Gould J, Tamayo P and Mesirov JP: GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics. 23:3251–3253. 2007. View Article : Google Scholar : PubMed/NCBI
16	Silletti S, Paku S and Raz A: Autocrine motility factor and the extracellular matrix. I coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization. Int J Cancer. 76:120–128. 1998. View Article : Google Scholar : PubMed/NCBI
17	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
18	Molinari M: Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 33:261–274. 2000. View Article : Google Scholar : PubMed/NCBI
19	Shi Y and Massagué J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
20	Wakefield LM and Roberts AB: TGF-beta signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 12:22–29. 2002. View Article : Google Scholar : PubMed/NCBI
21	Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I and Salzet M: Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 291:59–66. 2010. View Article : Google Scholar
22	Schmitz AA, Govek EE, Böttner B and Van Aelst L: Rho GTPases: signaling, migration, and invasion. Exp Cell Res. 261:1–12. 2000. View Article : Google Scholar : PubMed/NCBI
23	Aznar S and Lacal JC: Rho signals to cell growth and apoptosis. Cancer Lett. 165:1–10. 2001. View Article : Google Scholar : PubMed/NCBI
24	Fritz G, Just I and Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer. 81:682–687. 1999. View Article : Google Scholar : PubMed/NCBI
25	Abraham MT, Kuriakose MA, Sacks PG, Yee H, Chiriboga L, Bearer EL and Delacure MD: Motility-related proteins as markers for head and neck squamous cell cancer. Laryngoscope. 111:1285–1289. 2001. View Article : Google Scholar : PubMed/NCBI
26	Kamai T, Arai K, Tsujii T, Honda M and Yoshida K: Over-expression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int. 87:227–231. 2001. View Article : Google Scholar : PubMed/NCBI
27	Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T and Konishi I: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Inves. 83:861–870. 2003. View Article : Google Scholar
28	Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y and Oshima H: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 9:2632–2641. 2003.PubMed/NCBI
29	Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y, Yao X, Zheng Y and Fan D: Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res. 10:6239–6247. 2004. View Article : Google Scholar : PubMed/NCBI
30	Pille JY, Denoyelle C, Varet J, Bertrand JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, et al: Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther. 11:267–274. 2005. View Article : Google Scholar : PubMed/NCBI
31	Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA, Dong H, Chen X, Tokar B, Campbell SL, et al: ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 72:5338–5347. 2012. View Article : Google Scholar : PubMed/NCBI